- Do not use under age 2 years
- Respiratory Depression
- Apnea and death have occurred in children
- Severe tissue injury risk on Parenteral Injection
- Do not use Subcutaneous Injection
-
Hypotension with rapid IV injection
-
Extrapyramidal Side Effects (with high IV dose)
-
Anticholinergic effects (e.g. sedation, Dry Mouth)
- Pregnancy Category C
- Avoid in Lactation
- Long plasma Half-Life (observe prior to discharge)
- Lowers Seizure threshold
- Avoid use in children due to respiratory depression
- Absolutely contraindicated <2 years old
-
Nausea or Vomiting
- PO/PR/IM: 12.5 to 25 mg PO/Deep IM/PR every 4 to 6 hours
- IV (not FDA labeled, see adverse effects): 12.5 to 25 mg IV every 4 hours as needed
-
Motion Sickness
- PO/PR: 25 mg orally or PR 30 to 60 minutes prior to departure and every 12 hours as needed
- Dosing
-
Children (over age 2 years only)
- Children
- PO/PR/IM: 0.25 to 0.5 mg/kg (up to 25 mg/dose) PO/deep IM/PR every 4 to 6 hours
- IV (not FDA labeled, see adverse effects): 0.25 mg/kg/dose (up to 25 mg) IV every 4 hours as needed
-
Motion Sickness
- PO/PR: 0.5 mg/kg (up to 25 mg/dose) PO/PR 30 to 60 minutes prior to departure and every 12 hours as needed
- Less effective Antiemetic than Prochlorperazine (Compazine) in ER patients
- Ernst (2000) Ann Emerg Med 36(2): 89-94 [PubMed]
- Sedation may delay Emergency Department discharge
- Johnson (1993) Harriet Lane, Mosby, p. 521
- Hamilton (2020) Tarascon Pocket Pharmacopoeia
loading